FOLFIRI as second-line treatment of metastatic biliary tract cancer patients
Open Access
- 1 January 2019
- journal article
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 9 (2) , e2019087
Abstract
Autops Case Rep, vol.9, n2, e2019087, 2019Keywords
This publication has 31 references indexed in Scilit:
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2016
- Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published dataJournal of Experimental & Clinical Cancer Research, 2015
- Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entityCancer Medicine, 2015
- Second-line chemotherapy in advanced biliary cancer: a systematic reviewAnnals of Oncology, 2014
- Guidelines for the diagnosis and management of intrahepatic cholangiocarcinomaJournal of Hepatology, 2014
- Practical Guidelines for the Surgical Treatment of Gallbladder CancerJournal of Korean Medical Science, 2014
- Chemotherapy for cholangiocarcinoma: An updateWorld Journal of Gastrointestinal Oncology, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Recent Advances in the Management of CholangiocarcinomasSeminars in Liver Disease, 1994